BLOG

We Used to Have a Lyme Disease Vaccine. Are We Ready to Bring One Back?

The furthest along is a vaccine candidate co-developed by Pfizer, the U.S.-based pharmaceutical giant, and Valneva SE, a French biotech company. In March, the companies kicked off a Phase 2 trial in 600 people ages 5-65. The vaccine, which would be given in two to three doses, is very similar to LYMErix, but it targets six strains of Lyme bacteria—not just those common in North America, but in Europe as well—instead of the single strain that LYMErix targeted. Finding volunteers to take it has been easy, aside from a lull during COVID-19 lockdowns, says Thomas Lingelbach, president and CEO of Valneva. “The tick issue has reached a completely different scale,” he says. “Ticks are everywhere. Fortunately, there is a high and increasing level of awareness.”